Study #2024-0450
Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSIH/dMMR gastroesophageal junction/gastric cancer
MD Anderson Study Status
Enrolling
Treatment Agent
S095029, pembrolizumab 200 mg (KEYTRUDA ®)
Description
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Study phase:
Physician name:
Jaffer Ajani
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-888-653-5845
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.